These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 21784508)

  • 1. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
    Cirak S; Arechavala-Gomeza V; Guglieri M; Feng L; Torelli S; Anthony K; Abbs S; Garralda ME; Bourke J; Wells DJ; Dickson G; Wood MJ; Wilton SD; Straub V; Kole R; Shrewsbury SB; Sewry C; Morgan JE; Bushby K; Muntoni F
    Lancet; 2011 Aug; 378(9791):595-605. PubMed ID: 21784508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.
    Kinali M; Arechavala-Gomeza V; Feng L; Cirak S; Hunt D; Adkin C; Guglieri M; Ashton E; Abbs S; Nihoyannopoulos P; Garralda ME; Rutherford M; McCulley C; Popplewell L; Graham IR; Dickson G; Wood MJ; Wells DJ; Wilton SD; Kole R; Straub V; Bushby K; Sewry C; Morgan JE; Muntoni F
    Lancet Neurol; 2009 Oct; 8(10):918-28. PubMed ID: 19713152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy.
    Cirak S; Feng L; Anthony K; Arechavala-Gomeza V; Torelli S; Sewry C; Morgan JE; Muntoni F
    Mol Ther; 2012 Feb; 20(2):462-7. PubMed ID: 22086232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
    JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
    Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
    Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eteplirsen for the treatment of Duchenne muscular dystrophy.
    Mendell JR; Rodino-Klapac LR; Sahenk Z; Roush K; Bird L; Lowes LP; Alfano L; Gomez AM; Lewis S; Kota J; Malik V; Shontz K; Walker CM; Flanigan KM; Corridore M; Kean JR; Allen HD; Shilling C; Melia KR; Sazani P; Saoud JB; Kaye EM;
    Ann Neurol; 2013 Nov; 74(5):637-47. PubMed ID: 23907995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial.
    Wagner KR; Kuntz NL; Koenig E; East L; Upadhyay S; Han B; Shieh PB
    Muscle Nerve; 2021 Sep; 64(3):285-292. PubMed ID: 34105177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.
    Malerba A; Thorogood FC; Dickson G; Graham IR
    Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
    Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
    Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoring Dystrophin Expression with Exon 44 and 53 Skipping in the DMD Gene in Immortalized Myotubes.
    Echigoya Y; Yokota T
    Methods Mol Biol; 2023; 2587():125-139. PubMed ID: 36401027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy.
    Benny Klimek ME; Vila MC; Edwards K; Boehler J; Novak J; Zhang A; Van der Meulen J; Tatum K; Quinn J; Fiorillo A; Burki U; Straub V; Lu QL; Hathout Y; van Den Anker J; Partridge TA; Morales M; Hoffman E; Nagaraju K
    J Neuromuscul Dis; 2021; 8(s2):S369-S381. PubMed ID: 34569970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice.
    Vila MC; Novak JS; Benny Klimek M; Li N; Morales M; Fritz AG; Edwards K; Boehler JF; Hogarth MW; Kinder TB; Zhang A; Mazala D; Fiorillo AA; Douglas B; Chen YW; van den Anker J; Lu QL; Hathout Y; Hoffman EP; Partridge TA; Nagaraju K
    J Pathol; 2019 Jul; 248(3):339-351. PubMed ID: 30883742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen.
    Anthony K; Feng L; Arechavala-Gomeza V; Guglieri M; Straub V; Bushby K; Cirak S; Morgan J; Muntoni F
    Hum Gene Ther Methods; 2012 Oct; 23(5):336-45. PubMed ID: 23075107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.
    Echigoya Y; Lim KRQ; Melo D; Bao B; Trieu N; Mizobe Y; Maruyama R; Mamchaoui K; Tanihata J; Aoki Y; Takeda S; Mouly V; Duddy W; Yokota T
    Mol Ther; 2019 Nov; 27(11):2005-2017. PubMed ID: 31416775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production.
    Charleston JS; Schnell FJ; Dworzak J; Donoghue C; Lewis S; Chen L; Young GD; Milici AJ; Voss J; DeAlwis U; Wentworth B; Rodino-Klapac LR; Sahenk Z; Frank D; Mendell JR
    Neurology; 2018 Jun; 90(24):e2146-e2154. PubMed ID: 29752304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study.
    Komaki H; Takeshima Y; Matsumura T; Ozasa S; Funato M; Takeshita E; Iwata Y; Yajima H; Egawa Y; Toramoto T; Tajima M; Takeda S
    Ann Clin Transl Neurol; 2020 Dec; 7(12):2393-2408. PubMed ID: 33285037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Lancet; 2011 Aug; 378(9791):546-7. PubMed ID: 21784507
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.
    Frank DE; Schnell FJ; Akana C; El-Husayni SH; Desjardins CA; Morgan J; Charleston JS; Sardone V; Domingos J; Dickson G; Straub V; Guglieri M; Mercuri E; Servais L; Muntoni F;
    Neurology; 2020 May; 94(21):e2270-e2282. PubMed ID: 32139505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.